ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+173.6%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$352M
AUM Growth
+$352M
(+177%)
Cap. Flow
+$109M
Cap. Flow
% of AUM
31.11%
Top 10 Holdings %
Top 10 Hldgs %
66.01%
Holding
50
New
19
Increased
11
Reduced
5
Closed
14
Top Buys
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$20.1M |
| 2 |
Adverum Biotechnologies
ADVM
|
$15.2M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$12.3M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
$9.75M |
| 5 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$9.3M |
Top Sells
| 1 |
Arvinas
ARVN
|
$8.65M |
| 2 |
CRISPR Therapeutics
CRSP
|
$5.49M |
| 3 |
Protagonist Therapeutics
PTGX
|
$5.03M |
| 4 |
Veracyte
VCYT
|
$2.7M |
| 5 |
argenx
ARGX
|
$2.56M |
Sector Composition
| 1 | Healthcare | 95.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Axsome Therapeutics
AXSM
$6.05B
| $62.8M | 15.55% | 607,500 +85,000 | +16% | +$8.79M |
|
2
Arrowhead Research
ARWR
$3.05B
| $28.1M | 6.95% | 442,500 +55,000 | +14% | +$3.49M |
|
|
KDMN
3
DELISTED
Kadmon Holdings, Inc.
KDMN
| $27.4M | 6.78% | 6,040,000 -372,500 | -6% | -$1.69M |
|
4
Aurinia Pharmaceuticals
AUPH
$1.58B
| $21.4M | 5.31% | 1,057,500 +207,500 | +24% | +$4.2M |
|
|
ITCI
5
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $20.1M | 4.99% | +587,089 | New | +$20.1M |
|
6
Iovance Biotherapeutics
IOVA
$807M
| $18.2M | 4.5% | 656,500 -71,000 | -10% | -$1.97M |
|
|
7
Adverum Biotechnologies
ADVM
$64.6M
| $15.2M | 3.77% | +1,322,500 | New | +$15.2M |
|
|
8
Arvinas
ARVN
$568M
| $14.6M | 3.62% | 356,000 -210,500 | -37% | -$8.65M |
|
|
AVDL
9
Avadel Pharmaceuticals
AVDL
$1.43B
| $12.3M | 3.04% | +1,625,000 | New | +$12.3M |
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $12M | 2.98% | 917,500 +215,000 | +31% | +$2.82M |
|
11
Karyopharm Therapeutics
KPTI
$61.7M
| $11.3M | 2.8% | 590,000 +352,500 | +148% | +$6.76M |
|
|
12
BioCryst Pharmaceuticals
BCRX
$1.74B
| $9.75M | 2.41% | +2,825,000 | New | +$9.75M |
|
|
CNST
13
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $9.3M | 2.3% | +197,500 | New | +$9.3M |
|
|
DRNA
14
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $8.54M | 2.11% | +387,500 | New | +$8.54M |
|
15
Milestone Pharmaceuticals
MIST
$156M
| $8.14M | 2.02% | 508,500 +139,000 | +38% | +$2.23M |
|
|
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $7.81M | 1.93% | +910,000 | New | +$7.81M |
|
|
RETA
17
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $7.77M | 1.92% | 38,000 -7,000 | -16% | -$1.43M |
|
|
BLU
18
DELISTED
BELLUS Health Inc.
BLU
| $6.16M | 1.52% | 810,000 +25,000 | +3% | +$190K |
|
19
Apellis Pharmaceuticals
APLS
$3.48B
| $5.74M | 1.42% | +187,500 | New | +$5.74M |
|
20
Cartesian Therapeutics
RNAC
$261M
| $5.35M | 1.32% | +2,364,204 | New | +$5.34M |
|
21
Neurogene
NGNE
$264M
| $4.59M | 1.14% | +372,500 | New | +$4.59M |
|
|
KRTX
22
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $4.22M | 1.04% | +56,000 | New | +$4.22M |
|
23
Applied Therapeutics
APLT
$71M
| $4.04M | 1% | 148,000 +65,000 | +78% | +$1.77M |
|
24
Insmed
INSM
$28.8B
| $4.04M | 1% | 169,000 -51,000 | -23% | -$1.22M |
|
25
Kura Oncology
KURA
$686M
| $3.3M | 0.82% | 240,000 +145,000 | +153% | +$1.99M |
|